Triage Radiology Imaging Assessment for Greater Effectiveness (TRIAGE)
25 juin 2026 mis à jour par: King's College London
Triage Radiology Imaging Assessment for Greater Effectiveness (TRIAGE): a Cluster-Randomised Crossover Trial Evaluating the Reporting Turn-Around-Time of Brain Magnetic Resonance Images Using an AI-enabled Abnormality Detector for Prioritisation
The aim of the trial is to understand whether a computerised tool designed to quickly spot problems in brain scans (MIDI) can help doctors diagnose cases faster.
This will help patients by getting them the treatment they need sooner.
How useful doctors find the tool will also be measured, and whether it is cost-saving for the National Health Service (NHS).
Aperçu de l'étude
Description détaillée
NHS radiology services are under unprecedented pressure as rising demand outpaces available workforce capacity. MRI utilisation across the NHS has increased by 9% year-on-year. As a result, many departments have relied on unsustainable measures such as outsourcing and weekend insourcing to manage reporting backlogs.
Delays in scan reporting have serious implications, including missed or delayed diagnoses, prolonged hospital stays, higher healthcare costs, and poorer patient outcomes. A systematic review and meta-analysis found that each month of delay in initiating cancer treatment increases mortality risk by approximately 10%.
There is an urgent need for validated digital tools that can reduce TATs without compromising diagnostic accuracy. The TRIAGE study (Triage Radiology Imaging Assessment for Greater Effectiveness (TRIAGE): a Cluster-Randomised Crossover Trial Evaluating the Reporting Turn-Around-Time of Brain Magnetic Resonance Images using an AI-enabled Abnormality Detector for Prioritisation) evaluates whether MIDI can reduce the average TAT of abnormal scans in routine NHS clinical practice.
The primary purpose of MIDI is workflow triage: it enables prioritisation of abnormal scans within radiology reporting worklists, helping departments manage high volumes efficiently.
Type d'étude
Interventionnel
Inscription (Estimé)
100800
Phase
- N'est pas applicable
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Coordonnées de l'étude
- Nom: PCTU Trial Management team
- Numéro de téléphone: 00
- E-mail: pctu-triage@qmul.ac.uk
Sauvegarde des contacts de l'étude
- Nom: Giusi Manfredi, PhD
- Numéro de téléphone: 00
- E-mail: giusi.manfredi@kcl.ac.uk
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Non
La description
Inclusion Criteria:
For main trial
- Adult patient (≥ 18 years of age) at the time of MRI.
- Brain MRI scan performed at a participating NHS site during the defined study period (intervention or control arm).
- Brain MRI scan series will automatically be included if they contain the required scan sequences and are of the required resolution.
For O3 subgroup ● Radiologists, radiographers, and referring clinicians involved with the use of the MIDI tool at sites who consent to completing the staff survey
For O7 subgroup
- Adult patient (≥ 18 years of age) at the time of MRI.
- Brain MRI scan performed at a participating NHS site during the defined study period (intervention or control arm).
- Brain MRI scan series will automatically be included if they contain the required scan sequences and are of the required resolution.
- Patient with suspected de novo stroke/TIA in TIA/Stroke pathway.
- Patient with suspected de novo stroke/TIA in Acute Neurology pathway.
- Patient with suspected de novo stroke/TIA identified via SSNAP review.
For O8 subgroup
- Adult patient (≥ 18 years of age) at the time of MRI.
- Brain MRI scan performed at a participating NHS site during the defined study period (intervention or control arm).
- Brain MRI scan series will automatically be included if they contain the required scan sequences and are of the required resolution.
- Patient with stage III/IV malignant melanoma undergoing regular surveillance MRI brain scans presenting with de novo brain metastases.
- Patient with lung cancer undergoing pre-radical treatment staging MRI brain scans presenting with de novo brain metastases.
- Patients with de novo symptomatic brain metastases secondary to melanoma and/or lung cancer and/or breast cancer detected on MRI brain scans from all patient pathways.
Additionally for those completing EORTC questionnaires:
● Able to give consent and likely to be able to complete EORTC questionnaires.
Exclusion Criteria:
For main trial
- Patient is under 18 years of age at the time of MRI.
- Brain MRI scan not performed at a participating NHS site or outside the defined study period.
- Data will be excluded for those patients who have opted out of the use of their data for research under the National Data Opt-Out.
- Brain MRI scan series will automatically be excluded if they do not contain the required scan sequences and/or the required resolution.
For O3 subgroup ● Radiologists, radiographers, and referring clinicians involved with the use of the MIDI tool at sites who do not consent to completing the staff survey
For O7 subgroup
- Patient is under 18 years of age at the time of MRI.
- Brain MRI scan not performed at a participating NHS site or outside the defined study period.
- Data will be excluded for those patients who have opted out of the use of their data for research under the National Data Opt-Out.
- Brain MRI scan series will automatically be excluded if they do not contain the required scan sequences and/or the required resolution.
- Patient without suspected de novo stroke/TIA or not on TIA/Stroke pathway.
- Patient without suspected de novo stroke/TIA or not on Acute Neurology pathway.
For O8 subgroup
- Patient is under 18 years of age at the time of MRI.
- Brain MRI scan not performed at a participating NHS site or outside the defined study period.
- Data will be excluded for those patients who have opted out of the use of their data for research under the National Data Opt-Out.
- Brain MRI scan series will automatically be excluded if they do not contain the required scan sequences and/or the required resolution.
- Patient without stage III/IV malignant melanoma, or not undergoing regular surveillance MRI brain scans, or not presenting with de novo brain metastases.
- Patient without lung cancer undergoing pre-radical treatment staging MRI brain scans, or not presenting with de novo brain metastases.
- Patients without de novo symptomatic brain metastases secondary to melanoma and/or lung cancer and/or breast cancer detected on MRI brain scans.
Additionally for those completing EORTC questionnaires:
● Unable to give consent and unlikely to be able to complete EORTC questionnaires.
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Diagnostique
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Intervention - MIDI ON
Scans are triaged by the MIDI AI tool.
The system automatically classifies each MRI scan as either "normal" or "abnormal" shortly after image acquisition.
|
MIDI is an AI-based TRIAGE tool and its primary purpose is workflow triage of brain MRI scans.
|
|
Aucune intervention: Control - MIDI OFF
MRI scans are reported according to standard care in chronological order, with no AI prioritisation.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
Turnaround time for abnormal outpatient brain MRI scans
Délai: Time from abnormal MRI acquisition to radiologist report authorisation over 8 months.
|
Time from abnormal MRI acquisition to radiologist report authorisation over 8 months.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Turnaround time for abnormal inpatient brain MRI scans
Délai: Time from abnormal MRI acquisition to radiologist report authorisation over 8 months.
|
Time from abnormal MRI acquisition to radiologist report authorisation over 8 months.
|
|
|
Turnaround time for abnormal combined Brain MRI scans
Délai: Time from abnormal MRI acquisition to radiologist report authorisation over 8 months.
|
Time from abnormal MRI acquisition to radiologist report authorisation over 8 months.
|
|
|
Cost Effectiveness - Incremental cost per reduction in brain MRI scan turnaround time, radiologist reporting time, insourcing/outsourcing of reporting activity
Délai: From MRI scan acquisition to final radiologist report authorisation over 8 months.
|
From MRI scan acquisition to final radiologist report authorisation over 8 months.
|
|
|
Cost Effectiveness for patients with suspected TIA or Stroke - incremental cost per reduction in brain MRI turnaround time, time to diagnosis and time to treatment change
Délai: From MRI scan acquisition to initiation of treatment over 8 months.
|
From MRI scan acquisition to initiation of treatment over 8 months.
|
|
|
Cost Effectiveness for patients newly diagnosed with brain metastases secondary to melanoma, lung cancer, or breast cancer
Délai: From MRI scan acquisition to initiation of treatment within 8 months as well as from MRI scan acquisition to 28 and 90 days for mortality and 90 days for ECOG/KPS outcomes.
|
Incremental cost per change in turnaround time, time to diagnosis, time to treatment change, in 28-day mortality, in 90-day mortality, in ECOG/KPS at 90 days.
|
From MRI scan acquisition to initiation of treatment within 8 months as well as from MRI scan acquisition to 28 and 90 days for mortality and 90 days for ECOG/KPS outcomes.
|
|
Staff satisfaction - Questionnaire score from radiologists, radiographers, and referring clinicians, collected at month 6 of the intervention
Délai: From the start to month 6 of the intervention.
|
From the start to month 6 of the intervention.
|
|
|
Turnaround time for all brain MRI scans (normal and abnormal combined)
Délai: Time from MRI acquisition to final radiologist report acquisition over 8 months
|
Time from MRI acquisition to final radiologist report acquisition over 8 months
|
|
|
Turnaround Time for Critically Abnormal Brain MRI scans
Délai: Acquisition of critically abnormal brain MRI scans to final radiologist report authorisation over 8 months.
|
Acquisition of critically abnormal brain MRI scans to final radiologist report authorisation over 8 months.
|
|
|
Performance accuracy - MIDI assessment of abnormal/normal brain MRI scan, radiologist assessment of abnormal/normal brain MRI scan and reference standard of abnormal/normal brain MRI scan
Délai: MRI scan acquisition to final radiologist report authorisation over 8 months.
|
MRI scan acquisition to final radiologist report authorisation over 8 months.
|
|
|
Clinical Effectiveness Outcomes in patients with Suspected Transient Ischemic Attack/Stroke (time from MRI acquisition to definitive diagnosis, censoring or treatment change)
Délai: Time from MRI Acquisition to Definitive Diagnosis or Censoring, Time from MRI Acquisition to Treatment Change during Phase I and II (19 months)
|
Time from MRI Acquisition to Definitive Diagnosis or Censoring, Time from MRI Acquisition to Treatment Change during Phase I and II (19 months)
|
|
|
Proportion of diagnoses within 14 days in a subgroup of patients diagnosed with melanoma or lung cancer with de novo metastases
Délai: Within 14 days following index brain scan containing brain metastases
|
Within 14 days following index brain scan containing brain metastases
|
|
|
Mortality rates in a subgroup of patients diagnosed with melanoma or lung cancer with de novo metastases
Délai: Within 28 days following the index MRI brain scan and within 90 days following the index MRI brain scan
|
Within 28 days following the index MRI brain scan and within 90 days following the index MRI brain scan
|
|
|
Days alive and out of hospital following index MRI brain scan in a subgroup of patients diagnosed with melanoma or lung cancer with de novo metastases
Délai: Days alive and out of hospitals within 90 days following index MRI brain scan
|
Days alive and out of hospitals within 90 days following index MRI brain scan
|
|
|
Time to Treatment Change in a subgroup of patients diagnosed with melanoma or lung cancer with de novo metastases
Délai: Time from MRI scan acquisition to treatment (or censoring at the end of the data collection period) within 8 months.
|
Time from MRI scan acquisition to treatment (or censoring at the end of the data collection period) within 8 months.
|
|
|
Occurrence of treatment/SRS (Stereotactic Radiosurgery) treatment in a subgroup of patients diagnosed with melanoma or lung cancer with de novo metastases
Délai: Treatment - Within 48 days following index MRI brain scan Treatment with SRS - Within 90 days following index brain MRI scan
|
Treatment - Within 48 days following index MRI brain scan Treatment with SRS - Within 90 days following index brain MRI scan
|
|
|
Functional status using ECOG and KPS where possible in a subgroup of patients diagnosed with melanoma or lung cancer with de novo metastases
Délai: Within 90 days following index MRI brain scan
|
ECOG: Standardised 0 to 4 scale - 0 is fully active, 4 is completely disabled KPS - 10 to 100 scale - 10 is critically ill, 100 is no evidence of disease
|
Within 90 days following index MRI brain scan
|
|
Brain tumour-related Quality of Life in a consenting sub-group of patients with eligible brain metastases measured using EORTC QLQ-C30 questionnaire
Délai: At 90 days (± 14 days) following the index MRI brain scan
|
At 90 days (± 14 days) following the index MRI brain scan
|
|
|
Functional status in a consenting sub-group of patients with eligible brain metastases using ECOG and KPS scoring
Délai: At 90 days (± 14 days) following index MRI brain scan
|
ECOG: Standardised 0 to 4 scale - 0 is fully active, 4 is completely disabled KPS - 10 to 100 scale - 10 is critically ill, 100 is no evidence of disease
|
At 90 days (± 14 days) following index MRI brain scan
|
|
Brain tumour-related Quality of Life in a consenting sub-group of patients with eligible brain metastases measured using EORTC QLQ-BN20 questionnaire
Délai: At 90 days (± 14 days) following the index MRI brain scan
|
At 90 days (± 14 days) following the index MRI brain scan
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Les enquêteurs
- Chaise d'étude: Thomas C Booth, King's College London
Publications et liens utiles
La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.
Publications générales
- Hooper R, Teerenstra S, de Hoop E, Eldridge S. Sample size calculation for stepped wedge and other longitudinal cluster randomised trials. Stat Med. 2016 Nov 20;35(26):4718-4728. doi: 10.1002/sim.7028. Epub 2016 Jun 28.
- Hanna TP, King WD, Thibodeau S, Jalink M, Paulin GA, Harvey-Jones E, O'Sullivan DE, Booth CM, Sullivan R, Aggarwal A. Mortality due to cancer treatment delay: systematic review and meta-analysis. BMJ. 2020 Nov 4;371:m4087. doi: 10.1136/bmj.m4087.
- Candel MJ, van Breukelen GJ. Sample size calculation for treatment effects in randomized trials with fixed cluster sizes and heterogeneous intraclass correlations and variances. Stat Methods Med Res. 2015 Oct;24(5):557-73. doi: 10.1177/0962280214563100. Epub 2014 Dec 17.
- van Breukelen GJ, Candel MJ. Calculating sample sizes for cluster randomized trials: we can keep it simple and efficient! J Clin Epidemiol. 2012 Nov;65(11):1212-8. doi: 10.1016/j.jclinepi.2012.06.002.
- Powers DMW (2011). "Evaluation: From Precision, Recall and F-Measure to ROC, Informedness, Markedness & Correlation". Journal of Machine Learning Technologies. 2 (1): 37-63. doi:10.1186/s12880-015-0068-x.
- ClinicalTrials.gov. Study NCT04368481. https://clinicaltrials.gov/study/NCT04368481https://www.sciencedirect.com/science/article/pii/S1361841522000433
- Wood DA, Kafiabadi S, Busaidi AA, Guilhem E, Montvila A, Lynch J, Townend M, Agarwal S, Mazumder A, Barker GJ, Ourselin S, Cole JH, Booth TC. Deep learning models for triaging hospital head MRI examinations. Med Image Anal. 2022 May;78:102391. doi: 10.1016/j.media.2022.102391. Epub 2022 Feb 12.
- NHS England (2023). Faster Diagnosis Standard. https://www.england.nhs.uk/cancer/faster-diagnosis
- NICE (2022). Evidence Standards Framework for Digital Health Technologies. https://www.nice.org.uk/corporate/ecd7
- Rothwell PM et al. (2007). Early risk of stroke after a transient ischaemic attack. JAMA, 297(14), 1472-1482. https://jamanetwork.com/journals/jama/fullarticle/193353
- Royal College of Radiologists (2023). Clinical Radiology Workforce Census Report. https://www.rcr.ac.uk
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Estimé)
1 mars 2027
Achèvement primaire (Estimé)
1 mars 2030
Achèvement de l'étude (Estimé)
1 mars 2030
Dates d'inscription aux études
Première soumission
18 mai 2026
Première soumission répondant aux critères de contrôle qualité
25 juin 2026
Première publication (Réel)
26 juin 2026
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
26 juin 2026
Dernière mise à jour soumise répondant aux critères de contrôle qualité
25 juin 2026
Dernière vérification
1 juin 2026
Plus d'information
Termes liés à cette étude
Mots clés
Autres numéros d'identification d'étude
- 350683
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
NON
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Non
Étudie un produit d'appareil réglementé par la FDA américaine
Non
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .